Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe XXXX .

@entity1 @entity6987 @entity1569
BACKGROUND: Combining systemic agents with phototherapy is becoming a standard of care for @entity1 with moderate to severe @entity1569 . The combination of adalimumab and phototherapy has not been previously explored. METHODS: In this 24-week single-arm open-label study, adults with moderate to severe @entity1569 received adalimumab 40 mg every other week and narrowband (NB)-UVB phototherapy three times a week for 12 weeks and then were followed for 12 weeks without treatment. Response to therapy was determined using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA) affected and Physician's Global Assessment ( @entity6987 ) of @entity1569 . RESULTS: Twenty @entity1 were enrolled with mean baseline scores of 17.0 for PASI, 21.2 for BSA and 3.5 for @entity6987 . Half (10/20) of the @entity1 achieved PASI 75 response by week 4. At the end of treatment at week 12, 19 (95%) @entity1 achieved PASI-75, 15 (75%) @entity1 achieved PASI-90 and 11 (55%) @entity1 achieved PASI-100. Seventeen (85%) @entity1 were clear or almost clear ( @entity6987 score =1). Mean baseline PASI, BSA and @entity6987 scores improved by 95 percent, 93 percent and 80 percent, respectively. Disease improvement was observed through the end of follow up period at week 24. No serious adverse events were noted. CONCLUSION: Concurrent use of adalimumab and NB-UVB phototherapy was clinically effective and well tolerated in @entity1 with moderate to severe @entity1569 . This combination regimen represents a new treatment option for clinical practice and warrants further investigation in controlled clinical trials.
